Abstract
Background As hypercoagulability may result in recurrent miscarriages, anticoagulants (clexane) and aspirin (aspocid) could potentially increase live-birth rate in subsequent pregnancies in women with either inherited thrombophilia or unexplained recurrent miscarriages. Patients and methods This randomized trial included 120 pregnant women who were recruited by the closed-envelope method from the outpatient clinics of El-Hussien University Hospital and El-Galaa Maternity Teaching Hospital with history of at least three recurrent miscarriages. The trial was designed to compare the effects of low-dose aspirin (aspocid 75 mg tab) and low-molecular-weight heparin (LMWH) (clexane) on pregnancy outcome and live-birth rate. Pregnant women were divided into two groups: group 1 (60) was administered oral, low-dose aspirin (aspocid 75 mg tab) daily, and group 2 (60) was administered LMWH (clexane) 1 mg/kg subcutaneously daily. Results Regarding primary outcome (live-birth rate), the two groups did not differ significantly. Both drugs increased live-birth rate with an incidence of 81.7% in group 1 and 83.3% in group 2. Conclusion Low-dose aspirin (aspocid 75 mg tab) and LMWH (clexane 1 mg/kg) improve pregnancy outcome and increase live-birth rate, with no significant differences between the two drugs in patients with history of recurrent miscarriages without antiphospholipid antibody syndrome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
